

## WELLINGTON PARTNERS SELLS ITS SHARES IN DEFINIENS TO MEDIMMUNE

- *MedImmune strengthens immuno-oncology capabilities with acquisition of Definiens for an initial consideration of \$150 million*
- *First successful exit from the vintage 2013 Wellington Partners IV Life Science Fund less than 6 months after the initial investment*

Munich, 04 November 2014. AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically enhances the identification of biomarkers in tumour tissue.

Under the terms of the agreement, MedImmune will acquire 100 percent of Definiens' shares for an initial consideration of \$150 million and make additional predetermined milestone payments. Alongside the other shareholders, Wellington Partners Ventures IV Life Science Fund L.P. will sell its 10.75% stake in Definiens, which the fund acquired in June 2014 acting as new lead investor in a € 15 million growth financing round. Definiens will continue to operate its business with third-party customers.

Definiens' proprietary Cognition Network Technology® was developed by Professor Gerd Binnig, the 1986 Nobel Laureate in Physics, and unlocks information from cancer tissue samples by measuring the identity, locations and, most importantly, the relationships between the many and varied components of the complex tumour microenvironment.

The acquisition will strengthen MedImmune's focus on the discovery of novel predictive biomarkers in immuno-oncology. It is believed that using biomarkers to select patients for clinical trials could potentially shorten clinical timelines and increase response rates. As a result, the technology will serve as an important tool in the advancement of the most promising combination therapies in AstraZeneca's pipeline, around 80 percent of which currently has a personalised healthcare approach.

"MedImmune has a comprehensive programme in immuno-oncology and the identification of patients who are most likely to respond to particular therapies is critical to our ability to successfully develop new medicines," said Dr. Bahija Jallal, Executive Vice President, MedImmune. "Definiens' technology will complement our immuno-oncology approach and allow us to further accelerate our clinical programmes through its highly precise predictive and prognostic biomarker testing. We look forward to working with Definiens' scientists to give patients the best chance of receiving the targeted medicines suited for their particular needs."

"Definiens' Tissue Phenomics approach marks a significant step towards closing the gap between genomics and patient outcomes. We look forward to joining the MedImmune team as Tissue Phenomics is of particular importance for personalised medicine in immuno-oncology," said Thomas Heydler, Chief Executive Officer, Definiens. "Definiens' unique ability to extract information from tissue images enables us to find novel markers for patient stratification by correlating tissue information with clinical outcomes. Together, MedImmune and Definiens can bring tailored treatments to patients faster."

"This transaction is a win-win situation for all participants including the investors in our current fund Wellington Partners IV Life Science, which we closed in September 2013. It confirms our strategy to invest in leading innovators in the life science field in Europe, especially in the German-speaking areas, and to help innovators build their businesses and secure the best partnerships for accelerated growth", commented Dr. Rainer Strohmenger, General Partner at Wellington Partners.

The proposed transaction is expected to close in the fourth quarter of 2014.

Further information:

Dr. Rainer Strohmenger

General Partner

Tel: +49 89 21994116

Mail: [strohmenger@wellington-partners.com](mailto:strohmenger@wellington-partners.com)

### **About Wellington Partners**

Wellington Partners is among the most successful pan-European Venture Capital firms. With more than € 850 million under management and offices in Munich, London and Zurich, Wellington Partners invests in start-up companies throughout Europe that have the potential to become global leaders in the areas of digital media, resource efficiency and life sciences.

Since 1998, Wellington Partners has invested in more than 100 companies, including publicly listed firms like Actelion, Evolva, Gentigel, Implanet, Noemalife, Oxford Immunotec, Supersonic Imagine, Wavelight (acquired by Alcon) and Xing as well as privately held companies like AyoxxA, Grandis (acquired by Novartis), immatics, invendo medical, MPM Medical, MTM Laboratories (acquired by Roche), NEUWAY Pharma, Oxagen, Quanta, Sapiens, Sensimed, Symetis, ImmobilienScout24 (acquired by Deutsche Telekom) and Spotify. For further information, please visit [www.wellington-partners.com](http://www.wellington-partners.com).

### **About Definiens**

Definiens is the leading provider of image analysis and data mining solutions for tissue diagnostics and clinical digital pathology. Definiens technology provides detailed cell-by-cell readouts from target structures on tissue slides and allows the correlation of this information with data derived from other sources, generating new knowledge and supporting better decisions in research, diagnostics and therapy. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: [www.definiens.com](http://www.definiens.com).